Search | Clinical Trials Finder

Conditions: Cerebral Blood Flow, APOE 4
Interventions: FMD1 (LNT22-017-1), Dietary Guidance; Dietary Supplement · Behavioral
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 45 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Fibromuscular Dysplasia, Spontaneous Coronary Artery Dissection, Cervical Artery Dissection
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy, Muscular Dystrophy, Myotonic Dystrophy Type 1, Myotonic Dystrophy Type 2, Congenital Myotonic Dystrophy, PROMM (Proximal Myotonic Myopathy), Steinert's Disease, Myotonic Muscular Dystrophy
Interventions: Not listed
Lead sponsor: University of Rochester; Other
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2028
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Cardiovascular Disease
Interventions: ALT-711 (alagebrium chloride); Drug
Lead sponsor: Synvista Therapeutics, Inc; Industry
Eligibility: 50 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions: Losmapimod oral tablet, Placebo oral tablet; Drug
Lead sponsor: Fulcrum Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 12
States / cities: Irvine, California • Los Angeles, California • Gainesville, Florida + 9 more

Conditions: Facioscapulohumeral Muscular Dystrophy, Limb Girdle Muscular Dystrophy
Interventions: ATYR1940; Drug
Lead sponsor: aTyr Pharma, Inc.; Industry
Eligibility: 16 Years to 25 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Irvine, California • Stanford, California • Salt Lake City, Utah

Conditions: Hyperlipidemia
Interventions: Tetraethylammonium (TEA), L-NG-monomethyl Arginine (L-NMMA), Bradykinin, Sodium nitroprusside, Acetylcholine, Saline, Fluconazole; Drug
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 174 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Fibromuscular Dysplasia of Arteries, Fibromuscular Dysplasia, Spontaneous Coronary Artery Dissection
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Aging, Endothelial Dysfunction, Senescence
Interventions: COMP-4; Dietary Supplement
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 39 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Facioscapulohumeral Muscular Dystrophy
Interventions: ACE-083, ACE-083 or placebo; Drug
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 18
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 15 more

Conditions: Advanced Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Dietary Intervention, Educational Intervention, Electronic Health Record Review, Interview, Nutritional Assessment, Questionnaire Administration; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Facioscapulohumeral Muscular Dystrophy, Charcot-Marie-Tooth Disease
Interventions: ACE-083; Drug
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 19
States / cities: Orange, California • Sacramento, California • Aurora, Colorado + 16 more

Conditions: Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions: Losmapimod, Placebo oral tablet; Drug
Lead sponsor: Fulcrum Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 14
States / cities: Irvine, California • Los Angeles, California • Aurora, Colorado + 11 more

Conditions: Diabetes Mellitus
Interventions: ruboxistaurin, placebo; Drug · Other
Lead sponsor: Chromaderm, Inc.; Industry
Eligibility: 35 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Facioscapulohumeral Muscular Dystrophy
Interventions: FSHD-specific functional rating scale, Electrical Impedance Myography; Diagnostic Test · Device
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 8
States / cities: Los Angeles, California • Kansas City, Kansas • Baltimore, Maryland + 5 more

Conditions: Endothelial Dysfunction
Interventions: Galantamine, Placebo, TENS 7000; Drug · Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions: Placebo, ATYR1940; Biological
Lead sponsor: aTyr Pharma, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Rochester, New York • Columbus, Ohio

Conditions: Myotonic Dystrophy, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 5 Years and older
Enrollment: 465 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2028
U.S. locations: 5
States / cities: Boston, Massachusetts • Winston-Salem, North Carolina • Pittsburgh, Pennsylvania

Conditions: Inflammatory Bowel Diseases, Crohn Disease, Diet Modification
Interventions: Intermittent Reduced Calorie Diet (IRCD); Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Ovarian Cancer, Chemotherapeutic Toxicity
Interventions: Fasting Mimicking Diet (Xentigen by L'Nutra), Carboplatin, Paclitaxel, Standard diet; Dietary Supplement · Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Facioscapulohumeral Muscular Dystrophy
Interventions: ATYR1940; Biological
Lead sponsor: aTyr Pharma, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Facioscapulohumeral Muscular Dystrophy
Interventions: Not listed
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 18 Years to 100 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Facioscapulohumeral Muscular Dystrophy
Interventions: Testosterone Enanthate, Somatropin; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Endothelial Dysfunction
Interventions: Telmisartan; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 50 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

A Nutritional Intervention for Body, Brain, and Longevity Effects (NIBBLE)

Defining the Basis of Fibromuscular Dysplasia (FMD)

Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry

The STRETCH Study: Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic Hypertension

Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)

Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)

Endothelial Hyperpolarization in Humans

Survey on Physical Activity and Qualify of Life in Fibromuscular Dysplasia

COMP-4 Supplementation and Brachial Artery FMD

Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)

Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial

Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)

Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus

Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD

Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans

Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy

Biomarker Development for Muscular Dystrophies

Effects of an Intermittent Reduced Calorie Diet on Crohn's Disease

Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer

Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension

Bone Health in Facioscapulohumeral Muscular Dystrophy

Study of Testosterone and rHGH in FSHD

A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease